Professor Steen Knudsen, specializing in systems and molecular biology, advanced the understanding of how cancer cell lines in labs respond similarly to cancer in patients. This approach, linking drug sensitivity to tumor biology, was shared by CHOSA co-founder Peter Buhl Jensen and his collaborator Maxwell Sehested. Buhl and Sehested discovered that sensitivity and resistance patterns directly aligned with a drug’s mechanism of action.

From 2010, Knudsen and Jensen advanced DRP® technology together at Medical Prognosis Institute (MPI), in Copenhagen. In 2015, they co-founded Oncology Venture, focused on applying DRP® to select patients who would benefit from specific cancer treatments, while avoiding ineffective therapies.

Oncology Venture was founded by Peter Buhl Jensen, Ulla Hald Buhl, and Steen Knudsen, along with others. The company’s mission was to use the DRP® technology to guide the clinical development of cancer therapies. By pairing the right drug with the right patient, DRP® would enable precision medicine in oncology. Oncology Venture obtained the exclusive rights to license and commercialize DRP® technology, specifically focusing on its application in clinical oncology.

The Cisplatin Platin-DRP™ has a CE mark in the EU, which includes additional countries such as Norway, Lichtenstein, Turkey, Switzerland, Iceland.  Additionally  Platin-DRP™ has received an IDE approval with the FDA. These approvals demonstrate that the Platin-DRP™ is thoroughly validated.

The Platin-DRP™ has been clinically validated for cisplatin treatment in both breast and lung cancer through retrospective clinical studies. In addition, a prospective clinical study was completed and presented at ASCO in 2023, further supporting its predictive value. More recently, the Platin-DRP™ has also been validated for use in carboplatin-treated metastatic breast cancer patients, with results to be presented at ASCO.